Mohamed Aseafan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Cross Sectional

Metastatic Colorectal Cancer

Top Venues

JCO global oncology

BMC endocrine disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Yasmin Tuleimat, Nashwa Abdel-Aziz, Mervat Mahrous, Shereef Elsamany, Tusneem Elhassan, Mohammed Alghamdi
Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO global oncology 10 (2024)
Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Yasmin Tuleimat, Nashwa Abdel-Aziz, Mervat Mahrous, Shereef Elsamany, Tusneem Elhassan, Mohammed Alghamdi
Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO global oncology 10 (2024)
Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Yasmin Tuleimat, Nashwa Abdel-Aziz, Mervat Mahrous, Shereef Elsamany, Tusneem Elhassan, Mohammed Alghamdi
Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO global oncology 10 (2024)
Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Yasmin Tuleimat, Nashwa Abdel-Aziz, Mervat Mahrous, Shereef Elsamany, Tusneem Elhassan, Mohammed Alghamdi
Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO global oncology 10 (2024)
Shouki Bazarbashi, Mohamed Aseafan, Tasnim Elgazzar, Maha Alkhayat, Abdulrahman Alghabban, Marwa I Abdelgawad, Bader Alshamsan, Aisha Alshibany, Tusneem Elhassan, Ali Aljubran, Ahmed Alzahrani, Hindi Alhindi, Hussein Raef
Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre. BMC endocrine disorders 23 (1) (2023)